VC
Vivo Capital Portfolio holdings
AUM
$977M
This Quarter Return
+35.39%
1 Year Return
+209.68%
3 Year Return
+1,480.07%
5 Year Return
+2,591.98%
10 Year Return
–
AUM
$1.39B
AUM Growth
+$1.39B
(+26%)
Cap. Flow
+$54.5M
Cap. Flow
% of AUM
3.9%
Top 10 Holdings %
Top 10 Hldgs %
62%
Holding
63
New
10
Increased
3
Reduced
21
Closed
9
Top Buys
| 1 |
Legend Biotech
LEGN
|
$151M |
| 2 |
GTH
Genetron Holdings Limited ADS
GTH
|
$76.5M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$30.4M |
| 4 |
Celldex Therapeutics
CLDX
|
$20.8M |
| 5 |
Immunovant
IMVT
|
$19.5M |
Top Sells
| 1 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
$37.8M |
| 2 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$36.8M |
| 3 |
MEI Pharma
MEIP
|
$35.9M |
| 4 |
Ascendis Pharma
ASND
|
$30.4M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$17.6M |
Sector Composition
| 1 | Healthcare | 88.39% |
| 2 | Financials | 8.49% |
| 3 | Materials | 3.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $266M | 19.06% | 1,797,745 -205,402 | -10% | -$30.4M |
|
|
2
Legend Biotech
LEGN
$6.41B
| $151M | 10.85% | +3,555,007 | New | +$151M |
|
|
NFH
3
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
| $118M | 8.49% | 14,300,000 | – | – |
|
|
GTH
4
DELISTED
Genetron Holdings Limited ADS
GTH
| $76.5M | 5.49% | +6,339,860 | New | +$76.5M |
|
5
Passage Bio
PASG
$22.7M
| $60.9M | 4.37% | 2,229,587 | – | – |
|
|
AMRS
6
DELISTED
Amyris Inc.
AMRS
| $43.5M | 3.12% | 10,181,472 +3,689,225 | +57% | +$15.8M |
|
|
7
Crinetics Pharmaceuticals
CRNX
$2.92B
| $40.6M | 2.91% | 2,316,628 -1,004,173 | -30% | -$17.6M |
|
8
Arcutis Biotherapeutics
ARQT
$1.86B
| $39M | 2.8% | 1,289,360 -397,167 | -24% | -$12M |
|
|
SVA
9
DELISTED
Sinovac Biotech, Ltd
SVA
| $38.2M | 2.74% | 5,900,000 | – | – |
|
|
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $30.4M | 2.18% | +5,966,527 | New | +$30.4M |
|
11
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $29.3M | 2.1% | 1,151,622 +392,572 | +52% | +$10M |
|
|
AVDL
12
Avadel Pharmaceuticals
AVDL
$1.43B
| $28.5M | 2.04% | 3,526,093 -49,331 | -1% | -$399K |
|
|
KDMN
13
DELISTED
Kadmon Holdings, Inc.
KDMN
| $27.4M | 1.96% | 5,347,768 -7,191,747 | -57% | -$36.8M |
|
14
Zymeworks
ZYME
$1.12B
| $26.5M | 1.9% | 734,161 -367,075 | -33% | -$13.2M |
|
15
Arrowhead Research
ARWR
$3.05B
| $24.9M | 1.79% | 576,505 -192,169 | -25% | -$8.3M |
|
|
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $23.2M | 1.66% | 1,917,074 | – | – |
|
|
17
Celldex Therapeutics
CLDX
$1.47B
| $20.8M | 1.49% | +1,600,000 | New | +$20.8M |
|
|
18
Immunovant
IMVT
$2.56B
| $19.5M | 1.4% | +800,000 | New | +$19.5M |
|
19
Rocket Pharmaceuticals
RCKT
$354M
| $18M | 1.29% | 860,648 | – | – |
|
20
KalVista Pharmaceuticals
KALV
$678M
| $17.9M | 1.28% | 1,476,796 | – | – |
|
|
ZGNX
21
DELISTED
Zogenix, Inc.
ZGNX
| $17.8M | 1.28% | 658,523 -230,201 | -26% | -$6.22M |
|
|
EIGR
22
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $17.2M | 1.23% | 1,791,257 | – | – |
|
23
Kura Oncology
KURA
$686M
| $17.1M | 1.23% | +1,050,000 | New | +$17.1M |
|
24
Codexis
CDXS
$246M
| $17M | 1.22% | 1,493,903 | – | – |
|
|
MYOK
25
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $15.3M | 1.1% | 158,310 -175,311 | -53% | -$16.9M |
|